<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15033">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224874</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0302</org_study_id>
    <secondary_id>BMT CTN 0302</secondary_id>
    <secondary_id>U01HL069294-05</secondary_id>
    <secondary_id>285</secondary_id>
    <nct_id>NCT00224874</nct_id>
    <nct_alias>NCT00253656</nct_alias>
    <nct_alias>NCT00474149</nct_alias>
  </id_info>
  <brief_title>Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)</brief_title>
  <official_title>Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized Phase II, four arm treatment trial. The primary purpose of the
      study is to define new agents with promising activity against acute graft-versus-host
      disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Acute graft-versus-host disease (GVHD) is the major complication of allogeneic hematopoietic
      stem cell (HSC) transplantation. Acute GVHD produces significant morbidity and complicates
      patient management resulting in organ toxicity, frequent infections, malnutrition, and
      substantial delay in recovery from transplantation. Corticosteroids have been the primary
      therapy for acute GVHD for over three decades. Various additional immunosuppressive
      strategies have been tested as GVHD therapy but neither anti-thymocyte globulin (ATG),
      CD5-immunotoxins, IL-1 antagonists nor other agents have been demonstrably helpful in either
      control of GVHD symptoms or improvement in survival. Published response rates of complete
      response (CR) to acute GVHD therapy with corticosteroids range from 25-41%. These rates will
      be used as benchmarks for assessing efficacy of promising new agents. New immunosuppressive
      agents and strategies are required to improve the management of GVHD and decrease the
      toxicities of the immunosuppressive regimens.

      DESIGN NARRATIVE:

      In this trial, patients with newly diagnosed acute GVHD will be randomly assigned to receive
      corticosteroids plus one of four new agents (etanercept, MMF, denileukin diftitox [Ontak],
      and pentostatin). A control arm of only corticosteroids will not be employed. Each agent
      will be assessed for safety and efficacy (at least 35% complete remission [CR] rate at Day
      28 of therapy can be expected from previously untreated patients).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Complete Response (CR) at Day 28 of Therapy</measure>
    <time_frame>Measured at Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response at day 28 after randomization. CR was defined as resolution of all signs and symptoms of Graft-Versus-Host Disease (GVHD) in all evaluable organs in comparison to Day 1 scoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Partial Response (PR), Mixed Response (MR), and Progression</measure>
    <time_frame>Measured at Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Partial response, mixed response, and progression at Day 28 after randomization. Partial response was defined as improvement in one or more organs involved with Graft-Versus-Host Disease (GVHD) symptoms without progression in others. Mixed response was defined as improvement in one or more organs with deterioration in another organ manifesting symptoms of GVHD or development of symptoms of GVHD in a new organ. Progression was defined as deterioration in at least one organ without any improvement in others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Treatment Failure</measure>
    <time_frame>Measured at Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Graft-versus-host Disease (GVHD) Flares at Day 90</measure>
    <time_frame>Measured at Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Flares were defined as any increase in symptoms of or therapy for acute GVHD after an initial response (i.e., progression from an earlier CR or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Discontinuing Immune Suppression Without Flare</measure>
    <time_frame>Measured at Days 90, 180, and 270 post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunosuppression discontinuation was defined as the discontinuation of corticosteroids and all additional immunosuppressives, except cyclosporine or tacrolimus, for treatment of acute GVHD without subsequent flare by Day 90 post-initiation of therapy and later by discontinuation of all immunosuppressive medications, including cyclosporine or tacrolimus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chronic Graft-versus-host Disease (GVHD)</measure>
    <time_frame>Measured at 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with limited and extensive chronic GVHD at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Surviving at 6 and 9 Months Post Randomization</measure>
    <time_frame>Measured at 6 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Systemic Infections Within 3 Months of Initiation of Therapy</measure>
    <time_frame>Measured at 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Epstein-Barr Virus (EBV)-Associated Lymphoma</measure>
    <time_frame>Measured at 9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Immune System Disorders</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denileukin Diftitox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept [25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks].</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>ENBREL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].</description>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <other_name>CellCept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denileukin Diftitox</intervention_name>
    <description>Denileukin Diftitox (ONTAK®) [9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19].</description>
    <arm_group_label>Denileukin Diftitox</arm_group_label>
    <other_name>ONTAK®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentostatin</intervention_name>
    <description>Pentostatin [1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17</description>
    <arm_group_label>Pentostatin</arm_group_label>
    <other_name>Nipent®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior allogeneic hematopoietic stem cell transplant using either bone marrow,
             peripheral blood stem cells, or cord blood

          -  De novo acute GVHD diagnosed within 48 hours prior to enrollment; biopsy confirmation
             of GVHD is strongly recommended but not required; enrollment should not be delayed
             awaiting biopsy or pathology results; the patient must have had no previous systemic
             immune suppressive therapy given for treatment of acute GVHD except for a maximum 48
             hours of prior corticosteroid therapy (at least 1 mg/kg/day methylprednisolone)

          -  Patients that have undergone a scheduled donor lymphocyte infusion (DLI) as part of
             their original transplant therapy plan

          -  Absolute neutrophil count (ANC) greater than 500/µL

          -  Clinical status at enrollment to allow tapering of steroids to not less than 1
             mg/kg/day methylprednisolone (1.4 mg/kg/day prednisone) at Day 28 of therapy (e.g.,
             persisting malignant disease suggesting the need for accelerated taper of
             immunosuppression)

          -  Estimated creatinine clearance greater than 30 mL/minute

          -  Assent and educational materials provided to, and reviewed with, patients under the
             age of 18

        Exclusion Criteria:

          -  ONTAK, pentostatin, or etanercept given within 7 days of enrollment

          -  Active uncontrolled infection

          -  Patients that have undergone an unscheduled DLI, or DLI that was not part of their
             original transplant therapy plan

          -  If any prior steroid therapy (for indication other than GVHD), treatment at doses of
             at least 0.5 mg/kg/day methylprednisolone within 7 days prior to onset of GVHD

          -  Patients unlikely to be available at the transplant center on Day 28 and 56 of
             therapy

          -  A clinical syndrome resembling de novo chronic GVHD developing at any time after
             allotransplantation (see Chapter 2 of the BMT CTN Manual of Procedures for details of
             de novo chronic GVHD)

          -  Other investigational therapeutics for GVHD within 30 days, including agents used for
             GVHD prophylaxis

          -  Patients who are pregnant, breast feeding, or if sexually active, unwilling to use
             effective birth control for the duration of the study

          -  Adults unable to provide informed consent

          -  Patients with a history of intolerance to any of the study drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins/SKCCC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI/Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (Peds)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Clinical Trials Network Website</description>
  </link>
  <results_reference>
    <citation>Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16;114(3):511-7. doi: 10.1182/blood-2009-03-212290. Epub 2009 May 14.</citation>
    <PMID>19443659</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE, Weisdorf D. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2010 Mar;16(3):421-9. doi: 10.1016/j.bbmt.2009.11.010.</citation>
    <PMID>19925875</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D; Blood and Marrow Transplant Clinical Trials Network. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010 Dec;16(12):1693-9. doi: 10.1016/j.bbmt.2010.05.019. Epub 2010 Jun 9.</citation>
    <PMID>20541024</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>September 21, 2005</firstreceived_date>
  <firstreceived_results_date>January 29, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Graft vs Host Disease</keyword>
  <keyword>GVHD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Denileukin diftitox</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinic patients were recruited from August 2005 through March 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Mycophenolate Mofetil</title>
          <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Denileukin Diftitox</title>
          <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
        </group>
        <group group_id="P4">
          <title>Pentostatin</title>
          <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Mycophenolate Mofetil</title>
          <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Denileukin Diftitox</title>
          <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
        </group>
        <group group_id="B4">
          <title>Pentostatin</title>
          <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="47"/>
                <measurement group_id="B4" value="42"/>
                <measurement group_id="B5" value="180"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.9" spread="15.2"/>
                <measurement group_id="B2" value="40.6" spread="14.6"/>
                <measurement group_id="B3" value="47.4" spread="15.8"/>
                <measurement group_id="B4" value="50.5" spread="12.1"/>
                <measurement group_id="B5" value="46.0" spread="14.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="19"/>
                <measurement group_id="B4" value="15"/>
                <measurement group_id="B5" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="28"/>
                <measurement group_id="B4" value="27"/>
                <measurement group_id="B5" value="113"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="47"/>
                <measurement group_id="B4" value="42"/>
                <measurement group_id="B5" value="180"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Complete Response (CR) at Day 28 of Therapy</title>
        <description>Complete response at day 28 after randomization. CR was defined as resolution of all signs and symptoms of Graft-Versus-Host Disease (GVHD) in all evaluable organs in comparison to Day 1 scoring.</description>
        <time_frame>Measured at Day 28</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomized were included in the analysis on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Denileukin Diftitox</title>
            <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
          </group>
          <group group_id="O4">
            <title>Pentostatin</title>
            <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Complete Response (CR) at Day 28 of Therapy</title>
            <description>Complete response at day 28 after randomization. CR was defined as resolution of all signs and symptoms of Graft-Versus-Host Disease (GVHD) in all evaluable organs in comparison to Day 1 scoring.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Partial Response (PR), Mixed Response (MR), and Progression</title>
        <description>Partial response, mixed response, and progression at Day 28 after randomization. Partial response was defined as improvement in one or more organs involved with Graft-Versus-Host Disease (GVHD) symptoms without progression in others. Mixed response was defined as improvement in one or more organs with deterioration in another organ manifesting symptoms of GVHD or development of symptoms of GVHD in a new organ. Progression was defined as deterioration in at least one organ without any improvement in others.</description>
        <time_frame>Measured at Day 28</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomized were included in the analysis on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Denileukin Diftitox</title>
            <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
          </group>
          <group group_id="O4">
            <title>Pentostatin</title>
            <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Partial Response (PR), Mixed Response (MR), and Progression</title>
            <description>Partial response, mixed response, and progression at Day 28 after randomization. Partial response was defined as improvement in one or more organs involved with Graft-Versus-Host Disease (GVHD) symptoms without progression in others. Mixed response was defined as improvement in one or more organs with deterioration in another organ manifesting symptoms of GVHD or development of symptoms of GVHD in a new organ. Progression was defined as deterioration in at least one organ without any improvement in others.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Partial Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mixed Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Progression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Treatment Failure</title>
        <time_frame>Measured at Day 14</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Graft-versus-host Disease (GVHD) Flares at Day 90</title>
        <description>Flares were defined as any increase in symptoms of or therapy for acute GVHD after an initial response (i.e., progression from an earlier CR or PR).</description>
        <time_frame>Measured at Day 90</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomized were included in the analysis on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Denileukin Diftitox</title>
            <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
          </group>
          <group group_id="O4">
            <title>Pentostatin</title>
            <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With Acute Graft-versus-host Disease (GVHD) Flares at Day 90</title>
            <description>Flares were defined as any increase in symptoms of or therapy for acute GVHD after an initial response (i.e., progression from an earlier CR or PR).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16" lower_limit="0.21" upper_limit="0.49"/>
                  <measurement group_id="O2" value="12" lower_limit="0.14" upper_limit="0.40"/>
                  <measurement group_id="O3" value="15" lower_limit="0.21" upper_limit="0.49"/>
                  <measurement group_id="O4" value="15" lower_limit="0.21" upper_limit="0.50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Discontinuing Immune Suppression Without Flare</title>
        <description>Immunosuppression discontinuation was defined as the discontinuation of corticosteroids and all additional immunosuppressives, except cyclosporine or tacrolimus, for treatment of acute GVHD without subsequent flare by Day 90 post-initiation of therapy and later by discontinuation of all immunosuppressive medications, including cyclosporine or tacrolimus.</description>
        <time_frame>Measured at Days 90, 180, and 270 post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomized were included in the analysis on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Denileukin Diftitox</title>
            <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
          </group>
          <group group_id="O4">
            <title>Pentostatin</title>
            <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients Discontinuing Immune Suppression Without Flare</title>
            <description>Immunosuppression discontinuation was defined as the discontinuation of corticosteroids and all additional immunosuppressives, except cyclosporine or tacrolimus, for treatment of acute GVHD without subsequent flare by Day 90 post-initiation of therapy and later by discontinuation of all immunosuppressive medications, including cyclosporine or tacrolimus.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Day 90</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7" lower_limit="0.05" upper_limit="0.26"/>
                  <measurement group_id="O2" value="4" lower_limit="0.01" upper_limit="0.17"/>
                  <measurement group_id="O3" value="5" lower_limit="0.02" upper_limit="0.19"/>
                  <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 180</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12" lower_limit="0.13" upper_limit="0.39"/>
                  <measurement group_id="O2" value="13" lower_limit="0.16" upper_limit="0.42"/>
                  <measurement group_id="O3" value="8" lower_limit="0.06" upper_limit="0.28"/>
                  <measurement group_id="O4" value="8" lower_limit="0.07" upper_limit="0.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 270</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16" lower_limit="0.21" upper_limit="0.49"/>
                  <measurement group_id="O2" value="17" lower_limit="0.24" upper_limit="0.52"/>
                  <measurement group_id="O3" value="10" lower_limit="0.10" upper_limit="0.33"/>
                  <measurement group_id="O4" value="10" lower_limit="0.11" upper_limit="0.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chronic Graft-versus-host Disease (GVHD)</title>
        <description>Number of patients with limited and extensive chronic GVHD at 9 months</description>
        <time_frame>Measured at 9 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomized were included in the analysis on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Denileukin Diftitox</title>
            <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
          </group>
          <group group_id="O4">
            <title>Pentostatin</title>
            <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients With Chronic Graft-versus-host Disease (GVHD)</title>
            <description>Number of patients with limited and extensive chronic GVHD at 9 months</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Surviving at 6 and 9 Months Post Randomization</title>
        <time_frame>Measured at 6 and 9 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All patients randomized were included in the analysis on an intent-to-treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mycophenolate Mofetil</title>
            <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Denileukin Diftitox</title>
            <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
          </group>
          <group group_id="O4">
            <title>Pentostatin</title>
            <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients Surviving at 6 and 9 Months Post Randomization</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Month 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26" lower_limit="0.43" upper_limit="0.72"/>
                  <measurement group_id="O2" value="32" lower_limit="0.54" upper_limit="0.82"/>
                  <measurement group_id="O3" value="28" lower_limit="0.47" upper_limit="0.76"/>
                  <measurement group_id="O4" value="24" lower_limit="0.38" upper_limit="0.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22" lower_limit="0.32" upper_limit="0.61"/>
                  <measurement group_id="O2" value="29" lower_limit="0.48" upper_limit="0.76"/>
                  <measurement group_id="O3" value="24" lower_limit="0.34" upper_limit="0.62"/>
                  <measurement group_id="O4" value="21" lower_limit="0.31" upper_limit="0.62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Systemic Infections Within 3 Months of Initiation of Therapy</title>
        <time_frame>Measured at 3 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Epstein-Barr Virus (EBV)-Associated Lymphoma</title>
        <time_frame>Measured at 9 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Start of study through 9 months after randomization.</time_frame>
      <desc>Unexpected Adverse Events Included</desc>
      <group_list>
        <group group_id="E1">
          <title>Etanercept</title>
          <description>Patients received 25 mg Etanercept subcutaneously twice weekly for up to 4 weeks; discontinue if in Complete Response (CR) by 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Mycophenolate Mofetil</title>
          <description>Patients received Mycophenolate Mofetil (MMF) 20 mg/kg (maximum 1 gm) per oral or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Denileukin Diftitox</title>
          <description>Patients received Denileukin Diftitox 9 mcg/kg intravenously over 1 hour on days 1, 3, 5, 15, 17, 19.</description>
        </group>
        <group group_id="E4">
          <title>Pentostatin</title>
          <description>Patients received Pentostatin 1.5 mg/m2 intravenously daily on days 1-3 and 15-17.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy DiFronzo, Ph.D</name_or_title>
      <organization>National Heart, Lung, and Blood Institute</organization>
      <phone>301-435-0065</phone>
      <email>difronzon@nhlbi.nig.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
